Prove Episode Economics Before Scaling the Orthopedic Platform
Combined clinical beta results, site-specific ROI models, and business-development evidence into a field-tested business case before advancing investment.
01 · BUSINESS CHALLENGE
A versatile pressurized IV infusion system was designed as an alternative to hanging IV bags, gravity poles and manual hand pumps. Evidence was needed to determine where urgent buyer demand, regulatory requirements and unit economics could support commercialization.
01 · VERSATILE PLATFORM · UNCLEAR BEACHHEAD
The platform could serve veterinary care, home infusion, nutrient clinics and other settings, but plausible use did not prove buyer urgency, willingness to adopt or a viable purchase path.
02 · LARGE CATEGORY ≠ ACCESSIBLE ENTRY
High volume in hospital acute care and Urban EMS did not make either setting an accessible entry market. Installed pumps, clinical routines, workarounds and purchasing committees raised the switching burden.
03 · CONSTRAINED WORKFLOW · STRONGER PULL
Mobility, space constraints, rugged field conditions and limited clinician attention made legacy workflows less practical and created a reason to test pressure infusion.
04 · UNIT ECONOMICS
Pricing, reimbursement, distribution, purchasing cycles and willingness to trial varied by segment and required empirical validation.
02 · EXECUTIVE MANDATE
Leadership needed to prove three things before deeper capital and regulatory commitment: who had a real reason to switch, whether the economics and purchase path worked and what had to be true before scale.
01 · SWITCHING CASE
Confirm the workflow problem, buyer urgency, reachable users and willingness to trial.
02 · COMMERCIAL CASE
Test pricing, alternatives, buyer objections, service needs, and channel access.
03 · READINESS GATE
Define the product requirements and the manufacturing, regulatory, channel and financing conditions that had to be met.
View the assumptions tested →
03 · WORK ADDRESSED
The work connected buyer evidence to market selection, product requirements, unit economics, and Go / No Go decision support.
Market screening
KOL evidence
Commercial models
Requirements translation
Go / No Go prioritization
Readiness framing
↓
01
Frame target workflows, incumbent alternatives, adoption friction, and the hypotheses that would justify further validation.
02
Conduct moderated KOL customer sprints across approved subsegments and capture objections, workflow needs, and evidence of willingness to pay.
03
Build TAM/SAM, pricing, unit economics and labor value models while keeping modeled value separate from realized outcomes.
04
Translate segment evidence into market requirements and product roadmap inputs rather than assuming one configuration fits every market.
05
Use Go / No Go criteria to support the Urban EMS No Go recommendation, continue Flight EMS evaluation, prioritize Large Animal Field Veterinary modeling, and assess AERD as a standalone consumable path.
06
Develop manufacturing transfer, distribution and investor materials to support financing readiness without claiming completed execution or funds raised.
View how the validation cycle compressed from 90+ days to 30 days →
View the evidence to decision workflow →
View the market segmentation and Go / No Go workflow →
04 · RESULTS / EVIDENCE
Evidence supported a clear sequence: stop weak replacement paths, prioritize the strongest beachhead, and test the next bounded commitment.
PRIMARY PROOF · HISTORICAL MODELED VALUE / MRD VALIDATION
$498.4M
Spring 2020 MRD model; not revenue, share, valuation, or current market size.
DECISION PROOF · DOCUMENTED RECOMMENDATION
NO GO
May 3, 2019 No Go recommendation; not board or capital execution.
MECHANISM PROOF · MEASURED RESEARCH PROCESS RESULT
90 → 30d
90+ → 30 days from campaign launch to executive readout, Feb to May 2019.
View the historical submarket decision matrix →
HISTORICAL SUBMARKET DECISIONS
Buyer evidence, workflow fit, economics, and adoption constraints produced different answers by submarket: advance, pivot, continue testing, or stop.
| Segment / Submarket | Status | Historical TAM / SAM | Key workflow and commercial rationale |
|---|---|---|---|
| Large Animal Field Vet Equine / Bovine | PROCEED · PRIMARY BEACHHEAD | $498.4M Global modeled TAM | Field urgency, large volume infusions, and the 5L sleeve prototype created a stronger field use case. |
| Small Animal Standalone Drip Cup | PROCEED · PIVOT LINE | $30.9M U.S. modeled TAM | A standalone consumable addressed air in line alarms without requiring clinics to replace installed pumps. |
| Flight EMS / Air Medevac | PROCEED · PHASE I | $814K SAM $3.7B historical TAM | Space, altitude, and movement constraints strengthened the case for continuous pressure infusion. |
| Small Animal In Clinic Hardware | STOP · NO GO | N/A | 60 to 70% pump saturation and preference for automated pumps weakened the replacement hardware case. |
| Urban EMS Ground Transport | STOP · NO GO | $95.5B Total EMS market context | Short transport times, 80%+ receiving emergency department pump saturation, existing pressure cuff workarounds, and protocol changes weakened the entry case. |
| Hospital Acute Care | STOP · NO GO | N/A | 80%+ pump penetration, sunk capital, and Value Analysis Committee friction limited displacement opportunity. |
View supporting KPIs, economics, and planning evidence →
05 · OPERATING INSIGHT
Do not scale against an installed capital base until the switching case is proven. Test first where infrastructure constraints make the incumbent structurally weak.
CONVENTIONAL ASSUMPTION UNDER TEST
Hospital acute care and Urban EMS offered scale, familiar clinical use cases, and obvious technical relevance. On paper, replacing gravity or pump workflows appeared to create a broad commercialization opportunity.
DISCOVERED OPERATING REALITY
High pump penetration, short urban transport windows, and inexpensive workarounds reduced buyer urgency. Stronger pull appeared where mobility, field conditions, space constraints, or limited clinician attention made the existing workflow materially worse.
06 · STRATEGIC OUTPUTS
Evidence changed the sequence, not just the speed.
01 · MARKET ELIMINATION
Primary research supported No Go recommendations where short usage windows, installed pumps, and existing workarounds weakened the switching case, including Urban EMS and full hardware replacement in hospitals.
02 · PRODUCT UNBUNDLING
Rather than require full hardware replacement, later synthesis modeled a narrower standalone consumable path for AERD, representing a historical $30.9M U.S. modeled opportunity.
03 · BEACHHEAD SELECTION
Field conditions created a stronger reason to switch than saturated acute care environments. Later MRD modeling sized the Large Animal Field Veterinary opportunity at a historical modeled TAM of $498.4M.
07 · EXECUTIVE RELEVANCE
Use primary evidence to stop poor fit segments, reconfigure the offer when installed infrastructure blocks adoption, and deepen only where workflow failure creates a real reason to switch.
WHAT CHANGED
BEFORE
An IV platform with dual use potential had plausible applications across EMS, veterinary, home, and specialty care, but no defensible sequence for where to commit first.
EVIDENCE
43 moderated KOL customer sprints, workflow observations, market screening, requirements work, and commercial modeling separated weak replacement cases from stronger switching cases.
AFTER
The evidence supported constraining Urban EMS, continuing Flight EMS evaluation, prioritizing Large Animal Field Veterinary modeling, and assessing AERD as a standalone consumable path.
FOUR OPERATING RULES
01 · SWITCHING CASE
Fund where the current alternative fails in the real workflow, not where TAM is largest. If a cheap workaround is good enough in the actual time window, stop before business development and R&D costs compound.
02 · LEARNING VELOCITY
Compress capture, analysis, and readout so the commitment question is answered faster. The reported 90 to 30 day cycle is evidence about the research process, not proof of market success.
03 · OFFER DESIGN
When replacing the full system faces entrenched infrastructure, test whether a narrower or consumable path solves a paid problem inside existing budgets. Treat it as a modeled option, not a claimed launch.
04 · CAPITAL GATE
Advance only the next step that buyer pull, economics, channel access, manufacturing readiness, and regulatory requirements support. Release additional capital only as those dependencies clear.
When important decisions need operating experience, get principal-led support.
Principal-led advisory and operating leadership for executive teams facing consequential AI, governance, transformation, commercialization, and recovery mandates.
advisory@inteligems.io
